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Hepatocellular carcinoma (HCC) surveillance is associated with early tumor detection 
and improved survival in patients with cirrhosis; however, effectiveness is limited by 
underuse. We compared the effectiveness of mailed outreach and patient navigation 
strategies to increase HCC surveillance in a racially diverse cohort of patients with 
cirrhosis. We conducted a pragmatic randomized clinical trial comparing mailed 
outreach for screening ultrasound (n = 600), mailed outreach plus patient navigation (n 
= 600), or usual care with visit-based screening (n = 600) among 1800 patients with 
cirrhosis at a large safety-net health system from December 2014 to March 2017. 
Patients who did not respond to outreach invitations within 2 weeks received reminder 
telephone calls. Patient navigation included an assessment of barriers to surveillance 
and encouragement of surveillance participation. The primary outcome was HCC 
surveillance (abdominal imaging every 6 months) over an 18-month period. All 1800 
patients were included in intention-to-screen analyses. HCC surveillance was performed 
in 23.3% of outreach/navigation patients, 17.8% of outreach-alone patients, and 7.3% of 
usual care patients. HCC surveillance was 16.0% (95% confidence interval [CI]: 12.0%-
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20.0%) and 10.5% (95% CI: 6.8%-14.2%) higher in outreach groups than usual care (P 
< 0.001 for both) and 5.5% (95% CI: 0.9%-10.1%) higher for outreach/navigation than 
outreach alone (P = 0.02). Both interventions increased HCC surveillance across 
predefined patient subgroups. The proportion of HCC patients detected at an early 
stage did not differ between groups; however, a higher proportion of patients with 
screen-detected HCC across groups had early-stage tumors than those with HCC 
detected incidentally or symptomatically (83.3% versus 30.8%, P = 0.003). Conclusion: 
Mailed outreach invitations and navigation significantly increased HCC surveillance 
versus usual care in patients with cirrhosis. (H<SC>EPATOLOGY</SC> 2018;XX:XXXX.) 
 
Hepatocellular carcinoma (HCC) is the third-leading cause of cancer-related death 
worldwide.(1) HCC incidence in the United States and Europe has doubled over the past 
2 decades, and HCC is the leading cause of death in patients with cirrhosis.
Tumor stage is the strongest prognostic indicator in HCC patients, with curative 
treatments only available for patients with early-stage HCC. Ultrasound-based 
surveillance is associated with improvements in early detection and overall survival in 
at-risk patients, including those with cirrhosis, and is recommended by professional 
societies including the National Comprehensive Cancer Network, European Association 
for the Study of the Liver, and American Association for Study of Liver Diseases 
(AASLD).
(2) 
(3) A randomized clinical trial with more than 18,000 hepatitis B–infected 
persons demonstrated that HCC surveillance significantly lowered mortality by 37%.(4) 
Similarly, several cohort studies have shown that cirrhosis patients receiving HCC 
surveillance have higher odds of early detection and improved survival, after adjusting 
for lead-time bias, than those not receiving surveillance.
As with breast and colorectal cancer screening, HCC surveillance is typically only 
offered opportunistically during face-to-face clinic encounters.
(5-7) 
(8) Only a minority of 
cirrhosis patients undergo any HCC screening, and less than 5% undergo repeat semi-
annual surveillance.(9,10) Population outreach programs that systematically invite 
patients for screening and patient navigation interventions have effectively increased 
screening participation for other cancers including breast and colon cancer.(11-14) For 
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HCC, a mailed outreach strategy increased one-time screening participation in cirrhosis 
patients despite unique challenges surrounding patient identification, higher burden of 
medical illness, and patient access barriers to preventive care.(15)
This study reports the primary outcome of completing HCC surveillance every 6 
months over an 18-month period from a pragmatic, randomized clinical trial comparing a 
mailed outreach strategy, mailed outreach plus patient navigation, and usual care in 
patients with cirrhosis. 
 However, there are 
few data evaluating patient navigation strategies in cirrhosis patients, and the 
effectiveness of either intervention strategy to promote HCC surveillance over longer 
periods of time remains unknown. 
 
<H1>Methods</H1> 
<H2>STUDY POPULATION</H2> 
The trial was conducted at Parkland Health and Hospital System (Parkland) from 
December 2014 to March 2017. Parkland is a publicly funded integrated safety-net 
health system that includes a 900-bed hospital, 12 community-based primary care 
clinics, specialty hepatology and oncology clinics, and radiology suites. Parkland offers 
a sliding fee scale program, which provides access to primary and subspecialty medical 
care, including HCC surveillance, at low cost for uninsured Dallas County residents. 
The study was approved by the University of Texas (UT) Southwestern’s internal 
review board (IRB). The UT Southwestern IRB determined that a waiver of consent was 
ethical because (1) the study posed minimal risk, as HCC surveillance is standard of 
care and available for at-risk patients (including those with cirrhosis) through usual care; 
(2) waiver of consent would not adversely affect rights or welfare of participants; and (3) 
requiring consent would introduce volunteer bias threatening generalizability and validity 
as a population health strategy. 
The trial protocol (ClinicalTrials.gov #NCT01710215) is available in the 
Supporting Information. As previously described,(15) we used Parkland’s electronic 
medical record (EMR) to identify adult patients with documented or suspected cirrhosis 
and at least one outpatient clinic visit in the year preceding randomization. We included 
patients with suspected cirrhosis given many HCC patients fail to undergo screening 
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due to unrecognized cirrhosis.(16) “Documented cirrhosis” was defined using 
International Classification of Diseases, Ninth Revision (ICD-9) codes for cirrhosis or 
cirrhosis-related complications, which have high accuracy for identifying cirrhosis.(17) 
“Suspected cirrhosis” was initially defined as AST to platelet ratio index (APRI) greater 
than or equal to 1.0 in the presence of liver disease; however, the cut-off was increased 
to 1.5 in January 2015 to increase its positive predictive value for cirrhosis.(18) Patients 
with HCC or significant comorbid conditions, including Child C cirrhosis, were excluded 
given the limited benefit of HCC surveillance in those subgroups.(19)
 
 We also excluded 
patients with no address or phone number on file or language other than English or 
Spanish. 
<H2>RANDOMIZATION AND BLINDING</H2> 
Eligible persons were randomly assigned to receive usual care (group 1), mailed 
outreach invitations for abdominal ultrasound (group 2), or mailed outreach invitations 
plus patient navigation (group 3), allocated in a 1:1:1 ratio using a computer-generated 
randomization sequence. Randomization was stratified by documented versus 
suspected cirrhosis. Research staff conducted all mailings and reminder telephone 
calls; thus, participants and clinicians were blinded to the presence of other intervention 
groups. Although clinicians may have been aware of the trial, they did not have 
knowledge of group assignments. 
 
<H2>HCC SCREENING INTERVENTION COMPONENTS</H2> 
Usual care (all groups) included visit-based HCC surveillance as ordered by 
clinicians during any outpatient visit. Parkland clinics do not have HCC surveillance 
reminders or provider-level audit and feedback for performance. The Radiology 
department makes automated reminder calls to persons scheduled for ultrasounds 3 
days preceding the appointment. Radiology uses an EMR alert to inform clinicians of 
findings suspicious for HCC; however, use of this system is at the discretion of the 
interpreting radiologist.(20) Patients in the intervention groups were eligible for visit-
based surveillance as recommended through usual care. 
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Mailed outreach (groups 2 and 3) was initiated for each 6-month period with one-
page low-literacy letters in English and Spanish, providing basic information about HCC 
risk and recommending surveillance. Trained bilingual research staff conducted 
telephone calls using standardized scripts for persons who did not respond to mailed 
invitations within 2 weeks. Telephone calls were stopped for persons with nonworking 
phone numbers and those not reached after three attempts. Patients who did not 
complete screening were mailed a repeat letter recommending HCC surveillance 6 
months later. Patients with normal imaging received a letter informing them of the 
results and inviting them for repeat surveillance during the next 6-month period. Patients 
with an abnormal result were contacted by research staff and referred for diagnostic 
contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI). 
Patient navigation (group 3) included standardized phone scripts for research 
staff to explore barriers and encourage participation for those who declined surveillance 
during telephone calls. Research staff also called patients 5 to 7 days prior to 
ultrasound appointments to remind them of the appointment, address any concerns, 
and reschedule the appointment if needed. 
 
<H2>PRIMARY AND SECONDARY OUTCOMES</H2> 
The primary outcome was receipt of HCC surveillance, defined as completion of 
abdominal imaging (ultrasound, CT, or MRI) during each 6-month interval over the 18-
month study. Patient follow-up was censored at death or HCC diagnosis. For example, 
patients who completed surveillance every 6 months prior to death or HCC diagnosis 
were defined as meeting the primary outcome. For persons randomized to intervention 
groups, we included tests completed through outreach or usual care. To ascertain 
surveillance participation for all persons, research staff who did not deliver interventions 
and were blinded to intervention status queried the EMR for completed ultrasounds, 
contrast-enhanced CT, or contrast-enhanced MRI. Although professional societies do 
not recommend CT or MRI for screening, their completion satisfies the need for liver 
imaging and precludes the need for screening ultrasound. Alpha fetoprotein was not 
required because it was removed from AASLD guidelines during the study period. 
Subgroup analyses were planned a priori to examine effect modification by 
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race/ethnicity, documented versus suspected cirrhosis, Child-Pugh class, and receipt of 
hepatology care preceding randomization. 
A secondary outcome, defined a priori, was the proportion of patients with early-
stage HCC. HCC cases were adjudicated to confirm that they met AASLD diagnostic 
criteria (i.e., presence of a typical vascular pattern on imaging [arterial enhancement 
and delayed washout] or histology).(3)
Three post hoc secondary analyses were performed using more liberal 
definitions of surveillance completion. First, we compared the effectiveness of the 
interventions to promote HCC surveillance every 7 months over a 21-month period. 
Second, we compared receipt of one-time abdominal imaging during the 18-month 
study period among groups. Finally, we compared the proportion time covered (PTC) as 
the number of days patients were up-to-date with HCC surveillance, with each 
ultrasound providing 6 months (180 days) of time covered, divided by the number of 
days of follow-up (from randomization to date of HCC diagnosis, death, or study end).  
 The Barcelona Clinic Liver Cancer (BCLC) 
system was used for tumor staging, with early stage defined as BCLC stage 0 or A. 
 
<H2>STATISTICAL ANALYSIS</H2> 
We used intent-to-screen principles to guide the analyses. The Pearson chi-
square test was used to compare primary and secondary outcomes among groups. Our 
primary comparisons of interest were (1) outreach alone versus usual care and (2) 
outreach plus navigation versus outreach alone. Participants without outpatient visits 
after randomization were considered as lost to follow-up but retained in analyses. 
Univariate logistic regression analyses were conducted to evaluate for effect 
modification across patient subgroups. We performed a per-protocol analysis excluding 
patients who died or were diagnosed with HCC after randomization but prior to cohort 
entry. Missing data were rare and reported as unknown.  
Sample-size calculations were determined a priori to compare HCC surveillance 
across groups. With 600 persons randomly assigned to each group, we had 90% power 
to detect a difference of at least 7.1% in surveillance completion among groups, 
assuming surveillance completion of 10% in usual care at a prespecified two-sided 
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significance level of 0.025 (= 0.05/2 accounting for Bonferroni correction). Analyses 
were conducted using SAS 9.4 (SAS Institute Inc., Cary, NC). 
 
<H1>Results</H1> 
<H2>STUDY POPULATION</H2> 
Of the 1800 persons (mean age 55.3 years; 59.4% men), 600 were randomly 
assigned to mailed outreach and patient navigation, 600 to mailed outreach, and 600 to 
usual care (Fig. 1, Table 1). Participants were racially/ethnically diverse with 37.8% 
Hispanic, 32.1% black, and 28.3% white. Most (79.6%) patients had documented 
cirrhosis, and 20.4% had suspected cirrhosis. Most patients had compensated cirrhosis, 
with only 28.2% having ascites and 12.7% having hepatic encephalopathy. Although 
more than 90% of patients had one or more primary care visits in the year preceding 
randomization (median of four visits), only 25.7% had one or more hepatology clinic 
visits. One-third (31.1%) of patients received abdominal imaging within 6 months 
preceding randomization. 
 
<H2>PRIMARY OUTCOME: SURVEILLANCE COMPLETION</H2> 
HCC surveillance was performed in 23.3% (95% confidence interval [CI] 20.0%-
26.9%) of outreach/navigation patients, 17.8% (95% CI: 14.9%-21.1%) of outreach-
alone patients, and 7.3% (95% CI: 5.4%-9.7%) of usual care patients (Table 2). 
Compared with usual care, surveillance completion was significantly higher in outreach 
alone (+10.5%; 95% CI: 6.8%-14.2%) and outreach/navigation (+16.0%; 95% CI: 
12.0%-20.0%) groups (P < 0.001 for both). Adding navigation to outreach increased 
surveillance completion by 5.5% (95% CI: 0.9%-10.1%; P = 0.02) (Fig. 2). There was no 
appreciable change in direction or magnitude of results in a per-protocol analysis 
excluding persons who died (n = 4) or were diagnosed with HCC (n = 3) after 
randomization but prior to cohort entry. In this analysis, surveillance completion was 
significantly higher in both intervention groups compared with usual care (P < 0.001 for 
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both) and adding navigation increased surveillance completion compared with outreach 
alone (P = 0.02). 
There was no evidence of effect modification for either outreach alone or 
outreach/navigation interventions, compared with usual care, by race/ethnicity (white 
versus nonwhite) or presence of documented cirrhosis (documented versus suspected 
diagnosis); however, the magnitude of intervention effect varied by receipt of hepatology 
care in the year prior to randomization and Child-Pugh class (Supporting Figure S1A,B). 
Although CIs overlapped, the interventions (outreach alone and outreach/navigation 
versus usual care) had a stronger effect among patients with Child B cirrhosis and those 
who did not have hepatology care in the year preceding randomization. Among all 
predefined subgroups, patient navigation increased surveillance completion compared 
with outreach alone (Supporting Fig. S1C). 
 
<H2>SECONDARY OUTCOMES</H2> 
Secondary outcomes did not differ significantly among intervention groups. HCC 
was diagnosed in 1.8% (95% CI: 0.9%-3.3%) of outreach/navigation patients, 1.0% 
(95% CI: 0.4%-2.2%) of outreach-alone patients, and 2.3% (95% CI: 1.3%-3.9%) of 
usual care patients (Table 3). Similarly, the proportion of HCC patients detected at an 
early stage did not differ among study groups (P = 1.0), with 63.6% (95% CI: 30.8%-
89.1%) of outreach/navigation HCC patients, 66.7% (95% CI: 22.3%-95.7%) of 
outreach-alone HCC patients, and 57.1% (95% CI: 28.9%-82.3%) of usual care HCC 
patients diagnosed at an early stage. Cholangiocarcinoma was diagnosed in 1 patient in 
the outreach/navigation group. Of note, 8 (57.1%) HCC patients in the usual care group 
were screen-detected; conversely, 7 (41.2%) HCC patients in the intervention groups 
presented incidentally or symptomatically. Overall, screen-detected patients had a 
higher proportion of early stage tumors than those detected incidentally or 
symptomatically (83.3% versus 30.8%, P = 0.003) (Supporting Table S1). 
In a post hoc analysis evaluating a more liberal definition of HCC surveillance 
every 7 months over a 21-month period, 28.2% (95% CI: 24.6%-31.8%) of 
outreach/navigation patients, 20.8% (95% CI: 17.6%-24.1%) of outreach-alone patients, 
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and 9.5% (95% CI: 5.4%-9.7%) of usual care patients completed surveillance. HCC 
surveillance was 18.7% (95% CI: 14.4%-23.0%) and 11.3% (95% CI: 7.3%-15.3%) 
higher in outreach groups than usual care (P < 0.001 for both) and 7.4% (95% CI: 2.5%-
12.2%) higher for outreach/navigation than outreach alone (P = 0.003) (Supporting 
Table S2). Similarly, receipt of any abdominal imaging was 22.4% (95% CI: 16.9%-
27.8%) and 19.7% (95% CI: 14.2%-25.2%) higher in outreach/navigation and outreach-
alone groups than usual care (P < 0.001 for both), respectively (difference between 
outreach groups: 2.7% (95% CI: 0%-8.0%; P = 0.3) (Supporting Table S3). Finally, PTC 
was 25.3% (95% CI: 22.9%-27.6%) in the usual care group, 40.9% (95% CI: 38.3%-
43.6%) in the outreach-alone group, and 44.0% (95% CI: 41.2%-46.8%) in the 
outreach/navigation group. Both the outreach-alone and outreach/navigation groups 
had significantly higher PTC compared with usual care (P < 0.0001 for both); however, 
there was no significant difference between the two outreach groups (P = 0.11). 
 
<H1>Discussion</H1> 
In this pragmatic, randomized clinical trial among a large cohort of cirrhosis 
patients, a mailed outreach intervention significantly increased HCC surveillance every 
6 months compared with usual care. Adding patient navigation further increased HCC 
surveillance compared with outreach alone. Both interventions were effective, 
independent of patient sex, race/ethnicity, receipt of hepatology care, or presence of 
documented versus suspected cirrhosis, although the magnitude of benefit appeared 
stronger in patients with Child B cirrhosis and those not engaged in hepatology care. 
Despite improvements in the primary outcome, HCC surveillance in both intervention 
groups remained below 30%, highlighting a need for more intensive interventions. 
Despite literature demonstrating HCC surveillance underuse in cirrhosis patients, 
few studies have evaluated interventions to increase surveillance. Two small studies 
suggested a benefit of nursing protocols and automated reminders, but both were 
conducted among selected patients followed by hepatologists.(21) In clinical practice, 
primary care providers are often responsible for liver-related care of cirrhosis patients, 
particularly in rural areas where access to subspecialty care is limited.(22) Primary care 
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providers report several barriers to HCC surveillance, including inadequate knowledge 
and clinic time constraints, so it is unclear whether these interventions would be equally 
effective among these patients.(23) Another study suggested that EMR clinical reminders 
may increase HCC surveillance among cirrhosis patients followed by primary care 
providers, but this study relied on visit-based care and only included patients with 
documented cirrhosis.(24) Our study suggests that mailed outreach invitations can be an 
effective population health strategy to increase HCC surveillance among at-risk 
patients. Compared with other interventions, our mailed outreach strategy can increase 
surveillance participation among patients not regularly engaged in clinical care and 
those with suspected cirrhosis but without documented ICD-10 codes, who represent 
over one-third of patients failing to receive HCC surveillance.
Prior intervention studies only examined one-time or intermittent HCC 
surveillance completion, with none evaluating semi-annual surveillance, as 
recommended by AASLD guidelines. Our study extends this literature by demonstrating 
mailed outreach strategies, and patient navigation can increase HCC surveillance over 
longer periods of time. This is important because cirrhosis patients have a 2% to 4% 
annual risk of developing HCC. HCC surveillance at regular intervals is critical to 
identifying incident cancer at an early stage.
(16) 
(25,26) Our primary outcome of HCC 
surveillance moves a step closer to evaluating screening process completion, which 
includes initial screening, repeat screening among patients with normal screen results, 
and diagnostic evaluation among those with abnormal screen results. This distinction is 
important, as studies have demonstrated failures at each step in the HCC screening 
process.(9,27-29) Although semi-annual HCC surveillance is a more rigorous outcome 
than prior studies, this still represents an imperfect surrogate for clinical outcomes 
including early HCC detection and improved survival. Although we found no significant 
differences in early HCC detection among groups, our study was not powered to detect 
differences in tumor stage or survival. The lack of statistical power in our study was 
exacerbated by a lower than anticipated HCC incidence rate. It is unclear whether this 
was related to a lower incidence given increased dissemination of hepatitis C antiviral 
therapy and shift to nonviral cirrhosis, pragmatic trial design and imperfect specificity of 
ICD-9 codes for presence of cirrhosis, or ascertainment bias over the relatively short 18-
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month duration of the trial. An ongoing multicenter study is evaluating the effect of 
outreach strategies to improve outcomes such as screening process completion and 
early HCC detection, although this trial is years away from reporting. 
We found that patient navigation increased HCC surveillance every 6 months 
compared with outreach alone, with the benefit being more pronounced in a secondary 
analysis evaluating surveillance every 7 months. Prior studies have suggested high 
patient acceptance of HCC surveillance, although patient barriers, including challenges 
with scheduling and transportation, are associated with lower surveillance 
participation.(30,31) Patient navigation is an effective strategy to address screening 
barriers for other cancer screening programs but has not been previously evaluated for 
HCC surveillance.(12,32)
This study had the following limitations. First, our study was conducted in a 
safety-net health system and results may not generalize to other health systems. 
However, racially diverse, socioeconomically disadvantaged patients represent a 
difficult-to-reach population and are important to study, given lower HCC surveillance 
receipt and higher HCC mortality rates.
 Despite demonstrated effectiveness, less than one-third of 
patients receiving outreach and navigation in this study underwent HCC surveillance, 
highlighting a need for more intensive interventions. Patient navigation in our study 
consisted of only barrier assessment, motivational education, and assistance with 
ultrasound scheduling. More extensive navigation to overcome barriers, such as 
transportation assistance or evening/weekend ultrasound appointments so patients do 
not miss work, may be effective and warrant evaluation. Alternatively, prior studies have 
shown receipt of subspecialty care is significantly associated with higher surveillance 
rates, so efforts to increase referrals may be effective for systems with sufficient 
hepatology capacity. 
(33,34) Second, patients may have received 
abdominal imaging at outside institutions; however, this is unlikely because many 
patients did not have insurance for care outside of the safety-net health system. 
Furthermore, we would not expect receipt of surveillance imaging at outside institutions 
to differ among study groups given the randomized nature of the study. Third, low-
surveillance completion may be partly explained by patients no longer following at 
Parkland or having contraindications to screening (e.g., increased comorbidity or liver 
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function deterioration), which may be underrecognized given the trial’s pragmatic 
design. Fourth, we could not differentiate imaging indication (diagnostic versus 
screening purposes); however, imaging for either purpose is sufficient for surveillance 
completion. 
This study has several strengths including its large sample size with various 
cirrhosis etiologies, racially and socioeconomically diverse patient population, and 
innovation in comparing mailed outreach with and without patient navigation to promote 
HCC surveillance over 18 months. Our trial’s pragmatic design also avoided volunteer 
bias, included cirrhosis patients with minimal exclusion criteria, and used processes 
(ultrasound scheduling, outcome ascertainment, and results notification) that could 
easily be adopted into clinical care.(35
In summary, mailed outreach invitations are effective for increasing HCC 
surveillance among cirrhosis patients. Adding patient navigation to the outreach strategy 
further increased HCC surveillance. Given the pervasive nature of HCC-screening 
underuse among cirrhosis patients, mailed outreach with or without patient navigation 
can be an effective strategy for improving HCC screening delivery. 
) 
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FIG. 1. Study consort diagram. 
FIG. 2. HCC surveillance completion over 18-month study period by intervention group 
(HCC surveillance was defined as receipt of abdominal imaging during each 6-month 
period after randomization). Compared with usual care, HCC surveillance was 
significantly higher in the outreach-alone (+10.5%; 95% CI: 6.8%-14.2%) and 
outreach/navigation (+16.0%; 95% CI: 12.0%-20.0%) groups (P < 0.001 for both). 
Adding navigation to outreach increased the surveillance proportion by 5.5% (95% CI: 
0.9%-10.1%; P = 0.02). 
 
TABLE 1 Characteristics of Cirrhosis Patients Enrolled in a Pragmatic Randomized 
Clinical Trial Promoting HCC Surveillance, Overall and by Study Group 
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Usual Care 
(n = 600) 
Outreach 
Alone 
(n = 600) 
Outreach/ 
Navigation 
(n = 600) 
Total 
(n = 1800) 
Age (years) 
21-50 
51-60 
61-90 
 
183 (30.5) 
259 (43.2) 
158 (26.3) 
 
174 (29.0) 
272 (45.3) 
154 (25.7) 
 
158 (26.3) 
269 (44.8) 
173 (28.8) 
 
515 (28.6) 
800 (44.4) 
485 (26.9) 
Male sex (%) 350 (58.3) 361 (60.2) 358 (59.7) 1069 (59.4) 
Race/ethnicity (%) 
Non-Hispanic white 
Hispanic white 
Non-Hispanic black 
Other/Unknown 
 
182 (30.3) 
217 (36.2) 
186 (31.0) 
15 (2.5) 
 
165 (27.5) 
230 (38.3) 
197 (32.8) 
8 (1.3) 
 
163 (27.2) 
234 (39.0) 
195 (32.5) 
8 (1.3) 
 
510 (28.3) 
681 (37.8) 
578 (32.1) 
31 (1.7) 
Etiology of liver disease (%) 
Hepatitis C 
Alcohol-related 
Nonalcoholic steatohepatitis 
Hepatitis B 
Other/unknown 
 
320 (53.3) 
98 (16.3) 
104 (17.3) 
21 (3.5) 
57 (9.5) 
 
285 (47.5) 
115 (19.2) 
101 (16.8) 
27 (4.5) 
72 (12.0) 
 
313 (52.2) 
104 (17.3) 
94 (15.7) 
14 (2.3) 
75 (12.5) 
 
918 (51.0) 
317 (17.6) 
299 (16.6) 
62 (3.4) 
204 (11.3) 
Presence of documented cirrhosis (%) 472 (78.7) * 479 (79.8) 482 (80.3) 1433 (79.6) 
Hepatic decompensation (%) 181 (30.2) † 192 (32.0) 201 (33.5) 574 (31.9) 
Child-Pugh class  (% Child A)‡ 432 (72.0) 435 (72.5) 424 (70.7) 1291 (71.7) 
Charlson comorbidity index (%)† 
      
1 
0 
2 
3+ 
 
76 (12.7) 
140 (23.3) 
103 (17.2) 
281 (46.8) 
 
95 (15.8) 
143 (23.8) 
99 (16.5) 
263 (43.8) 
 
79 (13.2) 
149 (24.8) 
84 (14.0) 
288 (48.0) 
 
250 (13.9) 
432 (24.0) 
286 (15.9) 
832 (46.2) 
Number of primary care visits 4 (IQR 2-7) † 3 (IQR 2-7) 4 (IQR 2-7) 4 (IQR 2-7) 
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Usual Care 
(n = 600) 
Outreach 
Alone 
(n = 600) 
Outreach/ 
Navigation 
(n = 600) 
Total 
(n = 1800) 
Receipt of hepatology care 153 (25.5) † 153 (25.5) 157 (26.2) 463 (25.7) 
*Defined using ICD-9 codes for cirrhosis or cirrhosis-related complications.  
†During year prior to randomization. 
‡Defined using validated measure based on EMR data.
Abbreviation: IQR, interquartile range. 
(26) 
 
Intervention Group 
Completed 
HCC 
Surveillance
(n) 
* 
Proportion 
Completed 
Surveillance
(95% CI) 
  
 
Difference in Proportion Completing  
HCC Surveillance by Intervention Group 
(95% CI) 
vs. Usual Care vs. Outreach Alone 
 
Outreach/navigation  
(n = 600) 
140 23.3 (20.0-26.9) +16.0 (12.0-20.0) +5.5 (0.9-10.1) 
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TABLE 2 HCC Surveillance Completion Over 18-Month Study Period 
*
 
HCC surveillance was defined as receipt of abdominal imaging during each 6-month period 
after randomization. 
TABLE 3 Hepatocellular Carcinoma Surveillance Outcomes by Study Group 
*
 
Early HCC was defined as BCLC stage 0 or stage A. 
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http://onlinelibrary.wiley.com/doi/10.1002/hep.xxxxx/suppinfo. 
 
 
AQ1: Please confirm or correct the names of the authors, the affiliations, and the 
correspondence footnote (include academic degrees of the correspondence author up 
to highest achieved). 
AQ2: For all listed citations with two or more authors who share first authorship, 
HEPATOLOGY stipulates those authors’ names to be in bold type. It is the authors’ 
responsibility to ensure that these names appear in bold in the reference section when 
 
Outreach alone  
(n = 600) 
107 17.8 (14.9-21.1) +10.5 (6.8-14.2) — 
 
Usual care  
(n = 600) 
 
44 7.3 (5.4-9.7) — — 
Intervention Group 
 
Any-Stage HCC Diagnosis 
 
 
Early-Stage HCC Diagnosis
 
* 
n 
Study Group Percentage 
(95% CI) 
n 
HCC Diagnoses in Study 
Group Percentage 
(95% CI) 
Outreach/navigation 
(n = 600) 
11 1.8 (0.9-3.3) 7 of 11 63.6 (30.8-89.1) 
Outreach alone 
(n = 600) 
6 1.0 (0.4-2.2) 4 of 6 66.7 (22.3-95.7) 
Usual care 
(n = 600) 
14 2.3 (1.3-3.9) 8 of 14 57.1 (28.9-82.3) 
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Table 1: Characteristics of cirrhosis patients enrolled in a pragmatic randomized clinical trial 
promoting HCC surveillance, overall and by study group 
 
Usual 
Care 
n=600 
Outreach 
Alone 
n=600 
Outreach/ 
Navigation 
n=600 
Total 
N=1,800 
Age (years) 
21-50 
51-60 
61-90 
 
183 (30.5) 
259 (43.2) 
158 (26.3) 
 
174 (29.0) 
272 (45.3) 
154 (25.7) 
 
158 (26.3) 
269 (44.8) 
173 (28.8) 
 
515 (28.6) 
800 (44.4) 
485 (26.9) 
Male sex (%) 350 (58.3) 361 (60.2) 358 (59.7) 1,069 (59.4) 
Race/Ethnicity (%) 
Non-Hispanic White 
Hispanic White 
Non-Hispanic Black 
Other/Unknown 
 
182 (30.3) 
217 (36.2) 
186 (31.0) 
15 (2.5) 
 
165 (27.5) 
230 (38.3) 
197 (32.8) 
8 (1.3) 
 
163 (27.2) 
234 (39.0) 
195 (32.5) 
8 (1.3) 
 
510 (28.3) 
681 (37.8) 
578 (32.1) 
31 (1.7) 
Etiology of Liver Disease (%) 
Hepatitis C 
Alcohol-related 
Nonalcoholic steatohepatitis 
Hepatitis B 
Other/unknown 
 
320 (53.3) 
98 (16.3) 
104 (17.3) 
21 (3.5) 
57 (9.5) 
 
285 (47.5) 
115 (19.2) 
101 (16.8) 
27 (4.5) 
72 (12.0) 
 
313 (52.2) 
104 (17.3) 
94 (15.7) 
14 (2.3) 
75 (12.5) 
 
918 (51.0) 
317 (17.6) 
299 (16.6) 
62 (3.4) 
204 (11.3) 
Presence of documented cirrhosis (%)1 472 (78.7) 479 (79.8) 482 (80.3) 1,433 (79.6) 
Hepatic decompensation (%)2 181 (30.2) 192 (32.0) 201 (33.5) 574 (31.9) 
Child Pugh Class  (% Child A)3 432 (72.0) 435 (72.5) 424 (70.7) 1,291 (71.7) 
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Usual 
Care 
n=600 
Outreach 
Alone 
n=600 
Outreach/ 
Navigation 
n=600 
Total 
N=1,800 
Charlson Comorbidity Index (%)2 
      0 
1 
2 
3+ 
 
76 (12.7) 
140 (23.3) 
103 (17.2) 
281 (46.8) 
 
95 (15.8) 
143 (23.8) 
99 (16.5) 
263 (43.8) 
 
79 (13.2) 
149 (24.8) 
84 (14.0) 
288 (48.0) 
 
250 (13.9) 
432 (24.0) 
286 (15.9) 
832 (46.2) 
Number of primary care visits2 4 (IQR 2-7) 3 (IQR 2-7) 4 (IQR 2-7) 4 (IQR 2-7) 
Receipt of hepatology care2 153 (25.5) 153 (25.5) 157 (26.2) 463 (25.7) 
IQR – interquartile range 
1
 Defined using ICD-9 codes for cirrhosis or cirrhosis-related complications  
2
 During year prior to randomization 
3
 Defined using validated measure based on EMR data26 
Intervention Group 
Completed 
HCC 
Surveillance a 
(n) 
Proportion 
Completed 
Surveillance  
(95% CI) 
 
Difference in Proportion Completing  
HCC Surveillance by Intervention 
Group (95% CI) 
Au
th
or
 M
an
us
cr
ip
t
 This article is protected by copyright. All rights reserved 
Table 2. HCC surveillance completion over 18-month study period 
a
 HCC surveillance was defined as receipt of abdominal imaging during each 6-month period 
after randomization. 
Table 3. Hepatocellular carcinoma surveillance outcomes, by study group 
a
 Early HCC was defined as Barcelona Clinic Liver Cancer (BCLC) stage 0 or stage A.  
vs. Usual Care vs. Outreach Alone 
 
Outreach/Navigation  
(n=600) 
140 23.3 (20.0- 26.9) +16.0 (12.0- 20.0) +5.5 (0.9- 10.1) 
 
Outreach Alone  
(n=600) 
107 17.8 (14.9- 21.1) +10.5 (6.8- 14.2) --- 
 
Usual Care  
(n=600) 
 
44 7.3 (5.4- 9.7) --- --- 
Intervention Group 
 
Any Stage HCC Diagnosis 
 
 
Early Stage HCC Diagnosis a 
 
n 
% of study group, 
(95% CI) n 
%  of all HCC diagnoses 
in study group 
(95% CI) 
Outreach/Navigation 
(n=600) 11 1.8 (0.9 – 3.3) 7 of 11 63.6 (30.8 – 89.1) 
Outreach Alone 
(n=600) 6 1.0 (0.4 – 2.2) 4 of 6 66.7 (22.3 – 95.7) 
Usual Care 
(n=600) 14 2.3 (1.3 – 3.9) 8 of 14 57.1 (28.9 – 82.3) 
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